ACIU Form 144: Insider Sale of 45,000 Shares on 10/03/2025

Rhea-AI Filing Summary

AC Immune SA (ACIU) submitted a Form 144 notifying the proposed sale of 45,000 common shares through Morgan Stanley Smith Barney LLC on or about 10/03/2025 with an aggregate market value of $140,850.00. The filer acquired these shares on 06/01/2012 by previously exercised stock options and paid cash for them. The filing lists recent sales by the same account under 10b5-1 plans totaling multiple transactions between 07/24/2025 and 09/29/2025, including sales of 29,400 and 5,600 shares on 09/25/2025 and 09/29/2025, respectively. The filer attests no undisclosed material adverse information and includes standard Rule 144 representations.

Positive

• Securities acquired by previously exercised options on 06/01/2012, indicating clear acquisition source
• Sale to be executed through a registered broker (Morgan Stanley Smith Barney LLC) per Rule 144 procedures
• Filer attests no undisclosed material adverse information in the notice

Negative

• Proposed sale of 45,000 shares with aggregate value $140,850.00 (indicates insider disposition)
• Multiple 10b5-1 plan sales were executed recently between 07/24/2025 and 09/29/2025, showing prior insider sales

Insights

Insider Trading Compliance Analyst

TL;DR: A scheduled Rule 144 sale of 45,000 shares from previously exercised options; multiple recent 10b5-1 plan sales are disclosed.

The notice shows the shares were acquired by exercise on 06/01/2012 and are to be sold through Morgan Stanley Smith Barney LLC with an expected sale date of 10/03/2025.

The filing also documents several 10b5-1 plan sales between 07/24/2025 and 09/29/2025, indicating systematic dispositions already executed from the same account.

This document is procedural and complies with Rule 144 disclosure obligations; it contains no internal company performance data or new corporate actions.

FAQ

What is the proposed transaction disclosed in the ACIU Form 144?

The filing discloses a proposed sale of 45,000 common shares via Morgan Stanley Smith Barney LLC with an aggregate market value of $140,850.00, approximately dated 10/03/2025.

How were the 45,000 shares acquired according to the filing?

The shares were acquired on 06/01/2012 by previously exercised stock options, and payment was made in cash.

Has the filer sold other ACIU shares recently?

Yes. The filing lists several 10b5-1 sales between 07/24/2025 and 09/29/2025, including sales of 29,400 and 5,600 shares on 09/25/2025 and 09/29/2025, respectively.

Does the filing state any undisclosed material information about AC Immune?

The filer represents by signing the notice that they do not know any material adverse information regarding the issuer that has not been publicly disclosed.

Through which exchange and broker will the sale occur?

The sale is listed for NASDAQ and will be handled by Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 04:28 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001697107
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	AC IMMUNE SA
SEC File Number	001-37891
Address of Issuer	EPFL Innovation Park, Building B Lausanne SWITZERLAND 00000
Phone	41213459121
Name of Person for Whose Account the Securities are To Be Sold	ANDREA M.A PFEIFER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	45000	140850.00	100410377	10/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/01/2012	Previously Exercised Stock Options	Issuer			45000	06/01/2012	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ANDREA PFEIFER EPFL Innovation Park, Building B Lausanne V8 00000	Common	09/29/2025	5600	16844.24
10b5-1 Sales for ANDREA PFEIFER EPFL Innovation Park, Building B Lausanne V8 00000	Common	09/25/2025	29400	84621.40
10b5-1 Sales for ANDREA PFEIFER EPFL Innovation Park, Building B Lausanne V8 00000	Common	09/17/2025	5457	13859.69
10b5-1 Sales for ANDREA PFEIFER EPFL Innovation Park, Building B Lausanne V8 00000	Common	09/16/2025	8798	22152.48
10b5-1 Sales for ANDREA PFEIFER EPFL Innovation Park, Building B Lausanne V8 00000	Common	09/15/2025	3800	9500.00
10b5-1 Sales for ANDREA PFEIFER EPFL Innovation Park, Building B Lausanne V8 00000	Common	08/05/2025	600	1500.00
10b5-1 Sales for ANDREA PFEIFER EPFL Innovation Park, Building B Lausanne V8 00000	Common	07/25/2025	1245	3113.00
10b5-1 Sales for ANDREA PFEIFER EPFL Innovation Park, Building B Lausanne V8 00000	Common	07/24/2025	100	250.00

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of previously exercised options during the period of 06/01/2012 through 05/11/2016.
Date of Notice	10/03/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/27/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Andrea M.A. Pfeifer
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)